Incretin-based therapies represent a novel treatment for both T2DM and obesity, relying on the insulinotropic actions of the gut hormone GLP-1 and, most recently, on the combined action of GLP-1 and the GIP hormones. The gene discussed is GLP1R; the disease is obesity due to melanocortin 4 receptor deficiency.